Cover Image
市場調查報告書

單株抗體生技仿製藥的全球市場:2016∼2020年

Global mAb Biosimilars Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 372113
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
單株抗體生技仿製藥的全球市場:2016∼2020年 Global mAb Biosimilars Market 2016-2020
出版日期: 2016年09月23日 內容資訊: 英文 103 Pages
簡介

生技仿製藥有與原來的藥物同樣的生物學的特性,把同樣的疾病作為標的。全球單株抗體生技仿製藥市場,2015∼2022一年更新架年複合成長率 (CAGR) 被預測以4∼7%擴大。

本報告提供全球單株抗體生技仿製藥市場相關調查,市場現狀及成長預測,市場規模,各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 產品研發線

第6章 市場情況

  • 市場概要
  • 波特的五力分析

第7章 單株抗體生技仿製藥的全球市場:各用途市場市場區隔

  • 慢性及自體免疫疾病的單株抗體生技仿製藥市場
  • 腫瘤的單株抗體生技仿製藥市場

第8章 單株抗體生技仿製藥的全球市場:各地區市場區隔

  • 各地區市場
  • 歐洲
  • 亞洲
  • 其他各國

第9章 單株抗體生技仿製藥的全球市場:促進要素

  • 專利失效數的增加
  • 成本效益高的治療需求
  • 生技仿製藥的償付優點
  • 理想的政府法規

第10章 促進要素的影響

第11章 單株抗體生技仿製藥的全球市場:課題

  • 醫生想不開生技仿製藥處方
  • 複數的製造上的複雜
  • 藥物缺點相關風險
  • 生技仿製藥產品的有限取得性
  • 臨床實驗的招募臨床實驗對象的困難

第12章 促進要素與課題的影響

第13章 單株抗體生技仿製藥的全球市場:趨勢

第14章 供應商環境

  • 競爭模式

第15章 主要供應商分析

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

目錄
Product Code: IRTNTR10349

About Biosimilars

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

Technavio's analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:

  • Europe
  • Asia
  • ROW

Technavio's report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira

Other Prominent Vendors

  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Alvartis Pharma
  • Amega Biotech
  • Amgen
  • Apotex
  • Aspen
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Bharat Serums
  • Bio Sidus
  • Biogen
  • Bionovis
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Boston Oncology
  • Cipla
  • Coherus Biosciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Gedeon Richter
  • GeneScience Pharmaceuticals
  • GSK
  • Hetero Drugs
  • iBio
  • Intas Pharmaceuticals
  • JCR Pharmaceuticals
  • LG Lifesciences
  • Lonza
  • Merck
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfenex
  • Pfizer
  • Ranbaxy Laboratories
  • Roche Holding
  • Samsung Biologics
  • Sanofi
  • Synthon

Market driver

  • Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Physicians' reluctance to prescribe biosimilars
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Biosimilars: Overview
  • Comparative analysis of generic small molecules and biosimilars
  • Biosimilars market opportunities
  • Challenges for new entrants
  • Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Market segmentation by application

  • Global chronic and autoimmune diseases mAb biosimilars market
  • Global oncology mAb biosimilars market

PART 08: Geographical segmentation

  • Global mAb biosimilars market by geographical segmentation 2015-2020
  • mAb biosimilars market in Europe
  • mAb biosimilars market in Asia
  • mAb biosimilars market in rest of the world

PART 09: Market drivers

  • Rise in number of patent expiries
  • Need for cost-effective treatment
  • Reimbursement benefits for biosimilars
  • Favorable government regulations

PART 10: Impact of drivers

PART 11: Market challenges

  • Physicians' reluctance to prescribe biosimilars
  • Multiple manufacturing complexities
  • Risks related to drug failure
  • Limited availability of biosimilar products
  • Difficulties in patient recruitment for clinical trials

PART 12: Impact of drivers and challenges

PART 13: Market trends

  • Emergence of biosimilars
  • Outsourcing of manufacturing activities
  • Need for high investment in R&D
  • High growth in the emerging markets
  • Rising number of strategic collaborations

PART 14: Vendor landscape

  • Competitive scenario

PART 15: Key vendor analysis

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global mAb biosimilars market: Snapshot
  • Exhibit 03: Global mAb biosimilars market: Growth analysis
  • Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015
  • Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020
  • Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015
  • Exhibit 07: Definition of biosimilars by agencies
  • Exhibit 08: Comparison between generic small molecules and biosimilars
  • Exhibit 09: Impact of biosimilars cost savings on different sectors
  • Exhibit 10: Factors affecting success of biosimilars
  • Exhibit 11: Biosimilars industry: Point-of-view
  • Exhibit 12: Factors influencing uptake of biosimilars
  • Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants
  • Exhibit 14: Challenges for new entrants
  • Exhibit 15: Bio-betters and its impact on market
  • Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015
  • Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015
  • Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020
  • Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015
  • Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions)
  • Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
  • Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions)
  • Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot
  • Exhibit 24: Current and future trends in global mAb biosimilars market
  • Exhibit 25: Factors influencing the global mAb biosimilars market 2015
  • Exhibit 26: Five forces analysis
  • Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020)
  • Exhibit 28: Applications of mAb biosimilars and its impact on growth of market
  • Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis
  • Exhibit 30: Population aged 60 years and over (millions)
  • Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
  • Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
  • Exhibit 33: Global incidence of cancer 2015-2020 (millions)
  • Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions)
  • Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application
  • Exhibit 36: Global mAb biosimilars market segmentation by application 2015
  • Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020
  • Exhibit 38: Global mAb biosimilars market by geography 2015
  • Exhibit 39: Market penetration of originators and biosimilars by region/country
  • Exhibit 40: Global mAb biosimilars market landscape: Country analysis
  • Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis
  • Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions)
  • Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015
  • Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis
  • Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions)
  • Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015
  • Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis
  • Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions)
  • Exhibit 49: Benefits of mAb biosimilars to US healthcare system
  • Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015
  • Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market
  • Exhibit 52: Patent analysis of mAb in the US
  • Exhibit 53: Patent analysis of biologicals in Europe
  • Exhibit 54: Impact of drivers
  • Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends
  • Exhibit 58: Competitive assessment of vendors
  • Exhibit 59: Key vendors: Geographical presence 2015
  • Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
  • Exhibit 61: Biocon profile
  • Exhibit 62: Biocon: Metrics analysis
  • Exhibit 63: Biocon growth strategy matrix
  • Exhibit 64: Biocon: Opportunity assessment
  • Exhibit 65: Celltrion profile
  • Exhibit 66: Celltrion: Metrics analysis
  • Exhibit 67: Celltrion growth strategy matrix
  • Exhibit 68: Celltrion: opportunity assessment
  • Exhibit 69: Dr. Reddy's Laboratories profile
  • Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis
  • Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix
  • Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment
  • Exhibit 73: Hospira profile
  • Exhibit 74: Hospira: Metrics analysis
  • Exhibit 75: Hospira growth strategy matrix
  • Exhibit 76: Hospira opportunity growth assessment
Back to Top